Haematology Chemotherapy Protocols
Disclaimer:
The chemotherapy protocols available on this website are maintained by the Lancashire and South Cumbria Network Pharmacist David Barber. The Cancer Alliance is not responsible for the content or upkeep of the protocols. If you have any queries about the protocols please contact David Barber: Tel 01772 522339 or david.barber@lthtr.nhs.uk
Amyloidosis: Regimens for treating amyloidosis can be found on the National Amyloidosis Centre website
Protocols A-G
					 	
							ABVD July 2019
						
							Acalabrutinib-CLL-MPM-Oct22
						
							Alemtuzumab v2
						
							Ara C low dose v2
						
							ATG
						
							ATRA  Arsenic
						
							Azacitidine 5 day protocol (unlicensed) v1.0 2021-05-12
						
							Azacitidine v2
						
							BEACOPP escalated 2014
						
							Benda R NHL
						
							Bendamustine Thalidomide Dexamethasone
						
							Bortezomib dexamethasone v2
						
							Bosutinib
						
							Brentuximab
						
							Busulphan v2
						
							C-Thal Dex Att v2
						
							C-Thal Dex v2
						
							Carfilzomib dexamethasone
						
							Chlorambucil v2
						
							ChlVPP v2
						
							Cladribine-Revised v2
						
							CyBorDex
						
							Cyclo 1.5
						
							Cyclo 3.0
						
							Cyclo weekly v2
						
							Dara-VTD for newly diagnosed myeloma eligible for PBSCT Feb 2022
						
							Daratumumab
						
							Dasatinib v2
						
							DECC
						
							Dexamethasone high dose v2
						
							DexRC3
						
							DT PACE 2
						
							DVd protocol Final
						
							EPOCH R
						
							Etoposide 2
						
							FC CLL4 v2
						
							FC LY05 v2
						
							FC R v2
						
							Fludara v2
						
							GDCVP v1
						
							Gem Cis Dex
						
							GEM-P
						
							Gemcitabine v2
						
					
				
				
			Protocols H-N
					 	
							Hodgkins-MPM-Mar18
						
							Hydroxycarbamide v2
						
							Ibrutinib CLL
						
							Ibrutinib MCL
						
							Ibrutinib plus venetoclax regimen  FLAIR trial version 4 protocol draft
						
							Idarubicin dexamethasone Oct 2022
						
							Idelalisib Rituximab v2
						
							Imatinib v2
						
							Ixazomib Lenalidomide & Dexamethasone
						
							Lenalidomide dexamethasone for myeloma
						
							Lenalidomide for MDS
						
							Lenalidomide Rituximab (Subcut) v1 2020-07-16
						
							MATRIX v4
						
							Melphalan and Predisolone
						
							Melphalan v2
						
							Methotrexate High Dose
						
							Methylprednisolone HD v2
						
							Modified R-CHOP-like Chemotherapy
						
							MRCHOP
						
							MTP
						
							Myeloma guideline draft for Network  2018 UPDATE
						
							Nilotinib v2
						
							Nivolumab July 2024
						
							NORDIC v2
						
					
				
				
			Protocols O-Z
					 	
							Cyclophos oral AIHA June 2021
						
							Obinutuzumab and Bendamustine v1 - 2019-05
						
							Obinutuzumab Chlorambucil
						
							Obinutuzumab CVP
						
							oral weekly mtx for CTCL December 2021
						
							PAD bolus
						
							Panobinostat Bortezomib Dexamethasone
						
							PCNSDLBCL-Nov18
						
							Pentostatin 2
						
							Pixantrone
						
							Polatuzumab_Rituximab_Bendamustine
						
							Pomalidomide
						
							Ponatinib
						
							R-BAC(500)
						
							R-BAC(800)
						
							R-CODOX-M-over 65 v2
						
							R-CODOX-M-under 65 v2
						
							R-CVP 2
						
							R-DHAP
						
							R-ICE Fractionated
						
							R-ICE v2
						
							R-IVAC-over 65
						
							R-IVAC-under 65 v2
						
							RCD
						
							RCDa
						
							RCHOP-14 v2
						
							RCHOP-21 v2
						
							RGCVP v1
						
							Ritux + cladribine for relapsed HCL v2 2022-01-05
						
							Rituximab Bendamustine CLL
						
							Rituximab Chlorambucil CLL
						
							Rituximab Chlorambucil NHL
						
							Rituximab Gemcitabine v1
						
							Rituximab Jan 2021
						
							Rituximab Subcutaneous (Mabthera) Maintenance
						
							Rituximab Vel dex subcutaneous
						
							Rituximab Venetoclax
						
							Rsquared-Jan19-MPM
						
							Ruxolitinib
						
							Spanish AIDA
						
							Temzolomide_NHL
						
							Thalidomide v2
						
							UKALL 14 Maintenance
						
							VCD sc
						
							VCD v2
						
							VCD weekly
						
							Vel dex SUBCUTANEOUS
						
							Venetoclax
						
							VEPEM-B v2
						
							VMP v1
						
							VRCAP
						
							VTD 3 weekly v2
						
							VTD 4 weekly
						
							VTD weekly
						
							Zanubrutinib-WM-MPM-Oct22